medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number S1

<< Back

Ann Hepatol 2011; 10 (S1)

Extracorporeal liver support-albumin dialysis with the Molecular Adsorbent Recirculating System (MARS)

Mitzner SR

Language: English
References: 61
Page: 21-28
PDF size: 230.04 Kb.


ABSTRACT

Extracorporeal liver support has been a much studied topic throughout the last 50 years. Albumin dialysis as a therapeutic option for patients with acute liver failure or acute decompensation of chronic liver disease was introduced in the mid-nineties. The Molecular Adsorbent Recirculating System (MARS) is based on the concept of albumin dialysis and allows for the removal of protein-bound as well as water-soluble toxins. Besides its role as a sufficient volume expander human serum albumin is an important scavenger for molecules with pathophysiological relevance in liver failure. Albumin dialysis enables the selective regeneration of patient´s albumin resulting in an increase of albumin binding capacity. Clinically, an improvement of central and local hemodynamics as well as liver-, brain-, and kidney-functions were observed. Thus, the treatment can contribute to liver regeneration and stabilization of vital organ functions and thus help to bridge patients to liver transplantation or to recovery of native liver function. Proper patient selection is critical for clinical success. Aggressive treatment of infections and sepsis seems to be a decisive pre-requisite for its safe and efficient use. Cautious anticoagulation with heparin is the common standard. Citrate use is recommended for patients prone to bleeding. Today, albumin dialysis MARS is among the best studied liver support methods. It appears as a valuable therapeutic tool for the treatment of various complications of of liver failure, especially hemodynamic instability and hepatic encephalopathy. Further studies will need to help defining the optimal patient selection and technical process parameters such as sessionlength and frequency of treatment.


REFERENCES

  1. Ho DW, Fan ST, To J, Woo YH, Zhang Z, Lau C, Wong J. Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model. Gut 2002; 50: 869-76.

  2. Ash SR, Carr DJ, Sullivan TA. Sorbent suspension reactor for extracorporeal detoxification in hepatic failure or drug overdose. ASAIO J 2004; 50: lviii-lxv.

  3. Vienken J, Christmann H. How can liver toxins be removed? Filtration and adsorption with the Prometheus system. Ther Apher Dial 2006; 10: 125-31.

  4. Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver support-comparison of different methods. Ther Apher Dial 2006; 10: 108-17.

  5. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Nöldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12(Suppl.) 17: S75-82.

  6. Nadalin S, Heuer M, Wallot M, Auth M, Schaffer R, Sotiropoulos GC, Ballauf A, et al. Paediatric acute liver failure and transplantation: the University of Essen experience. Transpl Int 2007; 20: 519-27.

  7. Yuan JZ, Ye QF, Zhao LL, Ming YZ, Sun H, Zhu SH, Huang ZF, et al. Preoperative risk factor analysis in orthotopic liver transplantation with pretransplant artificial liver support therapy. World J Gastroenterol 2006; 12: 5055-9.

  8. Gaspari R, Avolio AW, Zileri Dal Verme L, Agnes S, Proietti R, Castagneto M, Gasbarrini A. Molecular adsorbent recirculating system in liver transplantation: Safety and efficacy. Transplant Proc 2006; 38: 3544-51.

  9. Chiu A, Chan LM, Fan ST. Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience. Liver Int 2006; 26: 695-702.

  10. Stefoni S, Colì L, Bolondi L, Donati G, Ruggeri G, Feliciangeli G, Piscaglia F, et al. Molecular adsorbent recirculating system (MARS) application in liver failure: clinical and hemodepurative results in 22 patients. Int J Artif Organs 2006; 29: 207-18.

  11. Novelli G, Rossi M, Pretagostini M, Pugliese F, Ruberto F, Novelli L, Nudo F, et al. One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc 2005; 37: 2557-9.

  12. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-58.

  13. Di Campli C, Santoro MC, Gaspari R, Merra G, Zileri Dal Verme L, Zocco MA, et al. Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure. Transplant Proc 2005; 37: 2547-50.

  14. Mitzner S, Stange J, Dillmann A, Winkler RE, Michelsen A, Knippel M, Schmidt R. Removal of protein-bound uremic toxins by albumin dialysis: in vivo results. Nephrol Dial Transplant 1999; 14: A201.

  15. Guo LM, Liu JY, Xu DZ, Li BS, Han H, Wang LH, Zhang WY, et al. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003; 23(Suppl. 3): 16-20.

  16. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, Jalan R. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10: 1109-19.

  17. Kurtovic J, Boyle M, Bihari D, Riordan SM. Nitric-oxidelowering effect of terlipressin in decompensated cirrhosis: comparison to the molecular adsorbent recirculating system and correlation with clinical status. Eur J Gastroenterol Hepatol 2004; 16: 1335-8.

  18. Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10: R108.

  19. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Internat J Artif Organs 1996; 19: 677-91.

  20. Stadlbauer V, Krisper P, Beuers U, Haditsch B, Schneditz D, Jung A, et al. Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. ASAIO J 2007; 53: 187-93.

  21. Auth MK, Kim HS, Beste M, Bonzel KE, Baumann U, Ballauff A, Wallot M, et al. Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children. J Pediatr Gastroenterol Nutr 2005; 40: 54-9.

  22. Isoniemi H, Koivusalo AM, Repo H, Ilonen I, Höckerstedt K. The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation. Transplant Proc 2005; 37: 1088-90.

  23. Di Campli C, Zocco MA, Gaspari R, Novi M, Candelli M, Santoliquido A, Flore R, et al. The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant Proc 2005; 37: 2551-3.

  24. Ilonen I, Koivusalo AM, Höckerstedt K, Isoniemi H. Albumin dialysis has no clear effect on cytokine levels in patients with life-threatening liver insufficiency. Transplant Proc 2006; 38: 3540-3.

  25. Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner C, Stauber RE. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006; 10: R169.

  26. Klammt S, Mitzner S, Stange J, Brinkmann B, Drewelow B, Emmrich J, Liebe S, et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur J Gastroenterol Hepatol 2007; 19: 257-63.

  27. Klammt S, Mitzner SR, Stange J, Loock J, Heemann U, Emmrich J, Reisinger EC, et al. Improvement of Albumin Binding Capacity is associated with improved survival in patients with decompensated liver cirrhosis. Liver Transpl 2008; 14: 1333-9.

  28. Mitzner S, Loock J, Peszynski P, Klammt S, Majcher- Peszynska J, Gramowski A, Stange J, et al. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS—a review of clinical, biochemical, and electrophysiological data. Metab Brain Dis 2002; 17: 463-75.

  29. Hetz H, Faybik P, Berlakovich G, Baker A, Bacher A, Burghuber C, Sandner SE, et al. Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: a pilot study. Liver Transpl 2006; 12: 1357-64.

  30. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003; 9: 290-7.

  31. Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005; 43: 142-8.

  32. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, Larsen FS, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-62.

  33. Camus C, Lavoué S, Gacouin A, Compagnon P, Boudjéma K, Jacquelinet C, Thomas R, et al. Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: impact of the duration of therapy. Ther Apher Dial 2009; 13: 549- 55.

  34. Sen S, Rose C, Ytrebø LM, Davies NA, Nedredal GI, Drevland SS, Kjønnø M, et al. Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: a randomized study. Crit Care Med 2006; 34: 158-64.

  35. Mitzner SR. Drain the brain: albumin dialysis for intracranial hypertension. Crit Care Med 2006; 34: 254-5.

  36. Saich R, Collins P, Ala A, Standish R, Hodgson H. Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur J Gastroenterol Hepatol 2005; 17: 585-8.

  37. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.

  38. Cárdenas A, Ginès P. Therapy insight: Management of hepatorenal syndrome. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 338-48.

  39. Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21: 111-23.

  40. Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 43-51.

  41. Mitzner SR. Albumin dialysis: an update. Curr Opin Nephrol Hypertens 2007; 16: 589-95.

  42. Koivusalo AM, Vakkuri A, Höckerstedt K, Isoniemi H. Experience of Mars therapy with and without transplantation in 101 patients with liver insufficiency. Transplant Proc 2005; 37: 3315-7.

  43. Braun C, Birck R, Singer MV, Schnuelle P, van der Woude FJ, Löhr M, et al. Life-threatening intoxication with methylene bis(thiocyanate): clinical picture and pitfalls. A case report. BMC Emerg Med 2006; 6: 5.

  44. Liu YH, Wang Y, Yu LX, Sun LY, Feng BL, Shen ZY, Wang MM. Artificial liver support molecular adsorbents recirculating system therapy as a bridge to re-transplantation in two cases of long anhepatic duration. Hepatobiliary Pancreat Dis Int 2004; 3: 316-7.

  45. Choi JY, Bae SH, Yoon SK, Cho SH, Yang JM, Han JY, Ahn BM, et al. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation - a pilot study. Liver Int 2005; 25: 740-5.

  46. Doria C, Mandalá L, Scott VL, Gruttadauria S, Marino IR. Fulminant hepatic failure bridged to liver transplantation with a molecular adsorbent recirculating system: a single-center experience. Dig Dis Sci 2006; 51: 47-53.

  47. Trittenwein G, Boigner H, Mostafa G, Burda G, Mühl A, Amann G, Pollak A. Bridging to transplantation in acute liver failure in a 7-month-old infant. Wien Klin Wochenschr 2006; 118: 298-301.

  48. Wai CT, Lim SG, Aung MO, Lee YM, Sutedja DS, Dan YY, Aw MM, et al. MARS: a futile tool in centres without active liver transplant support. Liver Int 2007; 27: 69-75.

  49. Bellmann R, Graziadei IW, Feistritzer C, Schwaighofer H, Stellaard F, Sturm E, Wiedermann CJ, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004; 10: 107-14.

  50. Montero JL, Pozo JC, Barrera P, Fraga E, Costán G, Domínguez JL, Muntané J, et al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant Proc 2006; 38: 2511-3.

  51. Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010; 53: 307-12.

  52. Pichon N, François B, Chevreuil C, Gaulier JM. Albumin dialysis: a new therapeutic alternative for severe diltiazem intoxication. Clin Toxicol (Phila) 2006; 44: 195-6.

  53. Lee KH, Lee MK, Sutedja DS, Lim SG. Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 2005; 25: 973-7.

  54. Lionte C, Sorodoc L, Simionescu V. Successful treatment of an adult with Amanita phalloides-induced fulminant liver failure with molecular adsorbent recirculating system (MARS). Rom J Gastroenterol 2005; 14: 267-71.

  55. El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R. First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 2004; 50: 332-7.

  56. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-onchronic liver failure: a systematic review. JAMA 2003; 289: 217-22.

  57. Hessel FP, Mitzner SR, Rief J, Guellstorff B, Steiner S, Wasem J. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease. Liver Int 2003; 23(Suppl. 3): 66-72.

  58. Hessel FP, Bramlage P, Wasem J, Mitzner SR. Costeffectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure. Eur J Gastroenterol Hepatol 2010; 22(2): 213-20.

  59. Kantola T, Mäklin S, Koivusalo AM, Räsänen P, Rissanen A, Roine R, Sintonen H, et al. Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure. World J Gastroenterol 2010; 16: 2227-34.

  60. Drexler K, Baustian C, Richter G, Ludwig J, Ramlow W, Mitzner S. Albumin dialysis molecular adsorbents recirculating system: impact of dialysate albumin concentration on detoxification efficacy. Ther Apher Dial 2009; 13: 393-8.

  61. Faybik P, Bacher A, Kozek-Langenecker SA, Steltzer H, Krenn CG, Unger S, Hetz H. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care 2006; 10: R24.




2020     |     www.medigraphic.com